Streetbeat News

Stock Prices

DAWN

Day One Biopharmaceuticals has filed with the SEC for an offering of up to 12.1 million shares by selling stockholders. This move could impact the company's stock price as it may affect supply and demand dynamics.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:14 pm

CRM

Salesforce has projected its fiscal year 2025 revenue to be between $37.7 billion and $38 billion, slightly below the market estimate of $37.84 billion.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:13 pm

AFRM

Affirm's shares are rising due to strong Q4 earnings and positive Q1 guidance.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:12 pm

PSTG

Pure Storage reported Q2 2025 earnings of $0.44 per share, surpassing the $0.37 estimate, and sales of $763.77M, exceeding the $755.08M estimate. This marks a 10.91% increase in sales from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:11 pm

VEEV

Veeva Systems reported better-than-expected Q2 2025 earnings with an adjusted EPS of $1.62, surpassing the $1.52 estimate. Sales also exceeded expectations at $676.181 million, marking a 14.56% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:11 pm

CRWD

CrowdStrike has released its financial guidance for fiscal year 2025, projecting adjusted EPS between $3.61 and $3.65, which is below the estimated $3.88. The company also forecasts revenue between $3.890 billion and $3.902 billion, falling short of the estimated $3.953 billion.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:10 pm

CRWD

CrowdStrike has announced its Q3 adjusted EPS guidance of $0.80-$0.81, which is below the estimated $0.96. The company also projects revenue between $979.2 million and $984.7 million, falling short of the $1.01 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:10 pm

TOVX

Theriva Biologics shares rose following the announcement of a US patent application notice of allowance for a treatment targeting C. Difficile disease and other antibiotic-induced GI tract adverse effects.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:09 pm

AFRM

Affirm Holdings reported better-than-expected Q4 2024 results with an adjusted EPS of $(0.14), beating the estimate of $(0.51). Sales reached $659 million, surpassing the $603.66 million estimate and marking a 47.82% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:08 pm

CRWD

CrowdStrike's shares rose following the release of its Q2 financial results, which surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 8:07 pm